Gregory Davis
Vermogen: 6 137 $ op 30-06-2026
Vermogen: 6 137 $ op 30-06-2026
Gregory Davis is currently Head-Research & Technology at Sangamo Therapeutics, Inc. since 2020.
Formerly, Dr. Davis was Head-Genome Engineering at Sigma-Aldrich, Inc. Education includes a doctorate from the University of Oklahoma and an undergraduate degree from the University of Texas at Austin.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 25-05-2026 | 113.654 ( 0,03% ) | 6 137 $ | 30-06-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| SANGAMO THERAPEUTICS, INC. | Hoofd Techniek/Wetenschap/O&O | 17-11-2023 |
| Bedrijven | Functie | Einde |
|---|---|---|
Sigma-Aldrich, Inc.
Sigma-Aldrich, Inc. Chemicals: Major DiversifiedProcess Industries Manufactures chemicals and chemical preparations | Corporate Officer/Principal | - |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 4 |
|---|---|
Sangamo Therapeutics, Inc.
Sangamo Therapeutics, Inc. BiotechnologyHealth Technology Operates as a genomic medicine company | Health Technology |
Sigma-Aldrich, Inc.
Sigma-Aldrich, Inc. Chemicals: Major DiversifiedProcess Industries Manufactures chemicals and chemical preparations | Process Industries |
University of Oklahoma
University of Oklahoma Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Texas at Austin
University of Texas at Austin Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Kies jouw editie
Alle financiële informatie op nationaal niveau